These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25257751)

  • 1. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.
    Voss SD; Glade-Bender J; Spunt SL; DuBois SG; Widemann BC; Park JR; Leary SE; Nelson MD; Adamson PC; Blaney SM; Weigel B
    Pediatr Blood Cancer; 2015 Jan; 62(1):45-51. PubMed ID: 25257751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
    Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
    Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
    Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
    Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
    Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
    Iwamoto FM; Lamborn KR; Robins HI; Mehta MP; Chang SM; Butowski NA; Deangelis LM; Abrey LE; Zhang WT; Prados MD; Fine HA
    Neuro Oncol; 2010 Aug; 12(8):855-61. PubMed ID: 20200024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
    Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
    Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Monk BJ; Minion LE; Coleman RL
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
    Gotink KJ; Verheul HM
    Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
    Geller JI; Fox E; Turpin BK; Goldstein SL; Liu X; Minard CG; Kudgus RA; Reid JM; Berg SL; Weigel BJ
    Cancer; 2018 Dec; 124(23):4548-4555. PubMed ID: 30394521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
    Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
    J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In pursuit of new anti-angiogenic therapies for cancer treatment.
    Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.